Prostate cancer therapy - Debiopharm

Drug Profile

Prostate cancer therapy - Debiopharm

Alternative Names: E2 agonist/GnRH agonist - Debiopharm; Estrogen agonist/gonadotrophin releasing hormone agonist - Debiopharm; GnRH agonist/E2 agonist - Debiopharm; Gonadotrophin releasing hormone agonist/estrogen agonist - Debiopharm; TRIO; TRIO - Debiopharm

Latest Information Update: 12 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Debiopharm
  • Class Hormones
  • Mechanism of Action Estrogen receptor agonists; Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 05 Sep 2005 Phase-I/II clinical trials in Prostate cancer in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top